Gram-negative sepsis continues to cause substantial morbidity and mortality. Much of the pathophysiology is believed to be caused by toxic bacterial cell wall molecules, including lipopolysaccharides (LPS), that cause direct toxicity and/or induce a secondary pro-inflammatory response. Our preliminary data indicate that LPS is released from dying bacteria that blood in complexes that contain three conserved outer membrane proteins (OMPs), and that these OMPs may have biological activity themselves. The three bacterial membrane proteins have been identified as outer membrane protein A (OmpA), peptidoyglycan associated lipoprotein (PAL), and murein lipoprotein (MLP). The overall objective of the proposal is to evaluate the role(s) of OmpA, PAL, and MLP in Gram-negative sepsis, with the ultimate goal of developing a strategy of treating sepsis with cross-reacting anti-OMP antibodies. Our first specific aim is to expand studies suggesting that there is a form of PAL released from the bacterial surface that floats at low density together with human lipoproteins. Our third specific aim is to study monoclonal and polyclonal IgG directed to epitopes on OmpA, PAL, and MLP for their ability to bind and neutralize the biological effects of each outer membrane protein and to promote opsinophagocyosis of LPS/OMP complexes. Our final specific aim is to study the protective efficacy of monoclonal and polyclonal immunoglobulin G directed to OmpA, PAL, and MLP in two models of Gram-negative infection. The studies should advance our fundamental understanding of the pathophysiology of Gram-negative sepsis. Each of the OMPs are highly conserved amongst clinical strains of Gram-negative bacteria. Therefore, a successful outcome of the project would provide a direct and immediate approach to developing anti-OMP antibodies for human use for the treatment of sepsis.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM059694-02
Application #
6363315
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Somers, Scott D
Project Start
2000-03-01
Project End
2004-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$293,771
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Zeng, Melody Y; Cisalpino, Daniel; Varadarajan, Saranyaraajan et al. (2016) Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens. Immunity 44:647-658
Lin, Tian; Sammy, Fatima; Yang, Huan et al. (2012) Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol 189:2017-22
Warren, H Shaw; Fitting, Catherine; Hoff, Eva et al. (2010) Resilience to bacterial infection: difference between species could be due to proteins in serum. J Infect Dis 201:223-32
Lin, Tian; Kwak, Young Ho; Sammy, Fatima et al. (2010) Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. J Infect Dis 202:624-32
Liang, Xueya; Lin, Tian; Sun, Guangjie et al. (2009) Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages. J Leukoc Biol 86:229-35
Warren, H Shaw (2009) Peroxisome proliferator-activated receptor-gamma agonists, control of bacterial outgrowth, and inflammation. Crit Care Med 37:773-4
Warren, H Shaw (2009) Editorial: Mouse models to study sepsis syndrome in humans. J Leukoc Biol 86:199-201
Bagchi, Aranya; Herrup, Elizabeth A; Warren, H Shaw et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178:1164-71
Valentine, Catherine H; Hellman, Judith; Beasley-Topliffe, Laura K et al. (2006) Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis. Mol Med 12:252-8
Liang, Michael D; Bagchi, Aranya; Warren, H Shaw et al. (2005) Bacterial peptidoglycan-associated lipoprotein: a naturally occurring toll-like receptor 2 agonist that is shed into serum and has synergy with lipopolysaccharide. J Infect Dis 191:939-48

Showing the most recent 10 out of 16 publications